{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:08:21Z","timestamp":1778260101532,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Medical Scientific Research Foundation of Zhejiang Province","award":["No.2022KY653"],"award-info":[{"award-number":["No.2022KY653"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03390-y","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T06:02:33Z","timestamp":1708063353000},"page":"1687-1695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases"],"prefix":"10.1007","volume":"26","author":[{"given":"Manyi","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keda","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4725-6084","authenticated-orcid":false,"given":"Yue","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"3390_CR1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S272552","author":"Y Saida","year":"2023","unstructured":"Saida Y, Watanabe S, Kikuchi T. Extensive-stage small-cell lung cancer: current landscape and future prospects. Onco Targets Ther. 2023. https:\/\/doi.org\/10.2147\/OTT.S272552.","journal-title":"Onco Targets Ther"},{"key":"3390_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021. https:\/\/doi.org\/10.1038\/s41572-020-00235-0.","journal-title":"Nat Rev Dis Primers"},{"key":"3390_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166557","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Cui Y, Zheng X, Zhao Y, Sun G. Small-cell lung cancer brain metastasis: from molecular mechanisms to diagnosis and treatment. Biochim Biophys Acta Mol Basis Dis. 2022. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166557.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"3390_CR4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"3390_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0736-3","author":"S Yang","year":"2019","unstructured":"Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019. https:\/\/doi.org\/10.1186\/s13045-019-0736-3.","journal-title":"J Hematol Oncol"},{"key":"3390_CR6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21785","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023. https:\/\/doi.org\/10.3322\/caac.21785.","journal-title":"CA Cancer J Clin"},{"key":"3390_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34346","author":"Y Yu","year":"2023","unstructured":"Yu Y, Chen K, Fan Y. Extensive-stage small-cell lung cancer: current management and future directions. Int J Cancer. 2023. https:\/\/doi.org\/10.1002\/ijc.34346.","journal-title":"Int J Cancer"},{"key":"3390_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.1771","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Wang Q, Li K, Shi J, Han B, Wu L, et al. P2.12\u201326 the impact of anlotinib for relapsed SCLC patients with brain metastases: a subgroup analysis of ALTER 1202. J Thorac Oncol. 2019. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.1771.","journal-title":"J Thorac Oncol"},{"key":"3390_CR9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0838","author":"S Jiang","year":"2020","unstructured":"Jiang S, Liang H, Liu Z, Zhao S, Liu J, Xie Z, et al. The impact of anlotinib on brain metastases of non-small cell lung cancer: post hoc analysis of a Phase III randomized control trial (ALTER0303). Oncologist. 2020. https:\/\/doi.org\/10.1634\/theoncologist.2019-0838.","journal-title":"Oncologist"},{"key":"3390_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02869-9","author":"X Zhang","year":"2021","unstructured":"Zhang X, Zeng L, Li Y, Xu Q, Yang H, Lizaso A, et al. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. Cancer Immunol Immunother. 2021. https:\/\/doi.org\/10.1007\/s00262-021-02869-9.","journal-title":"Cancer Immunol Immunother"},{"key":"3390_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.04.001","author":"WZ Wang","year":"2022","unstructured":"Wang WZ, Shulman A, Amann JM, Carbone DP, Tsichlis PN. Small cell lung cancer: subtypes and therapeutic implications. Semin Cancer Biol. 2022. https:\/\/doi.org\/10.1016\/j.semcancer.2022.04.001.","journal-title":"Semin Cancer Biol"},{"key":"3390_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5360","author":"L Yu","year":"2023","unstructured":"Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R. Efficacy and safety of anlotinib combined with pd -1\/ pd-l1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer. Cancer Med. 2023. https:\/\/doi.org\/10.1002\/cam4.5360.","journal-title":"Cancer Med"},{"key":"3390_CR13","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2008.n.006","author":"G Chen","year":"2008","unstructured":"Chen G, Huynh M, Chen A, Fehrenbacher L, Gandara D, Lau D. Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer. 2008. https:\/\/doi.org\/10.3816\/CLC.2008.n.006.","journal-title":"Clin Lung Cancer"},{"key":"3390_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.568568","author":"H Li","year":"2021","unstructured":"Li H, Xue R, Yang X, Han S, Yang W, Song X, et al. Best supportive care versus whole-brain irradiation, chemotherapy alone, or WBRT plus chemotherapy in patients with brain metastases from small-cell lung cancer: a case-controlled analysis. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.568568.","journal-title":"Front Oncol"},{"key":"3390_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2216-8","author":"AS Berghoff","year":"2016","unstructured":"Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G, Dieckmann K, et al. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). J Neurooncol. 2016. https:\/\/doi.org\/10.1007\/s11060-016-2216-8.","journal-title":"J Neurooncol"},{"key":"3390_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/nature14432","author":"A Louveau","year":"2015","unstructured":"Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015. https:\/\/doi.org\/10.1038\/nature14432.","journal-title":"Nature"},{"key":"3390_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6433","author":"J Lu","year":"2023","unstructured":"Lu J, Lei X, Zhang P, Du L, Zhang Z, Qu B. Meta-analysis of pd -(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer. Cancer Med. 2023. https:\/\/doi.org\/10.1002\/cam4.6433.","journal-title":"Cancer Med"},{"key":"3390_CR18","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn371439-20201012-00025","author":"M Zhang","year":"2021","unstructured":"Zhang M, Hong Lu. Anlotinib in the treatment of small cell lung cancer with brain metastases. J Int Oncol. 2021. https:\/\/doi.org\/10.3760\/cma.j.cn371439-20201012-00025.","journal-title":"J Int Oncol"},{"key":"3390_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107379","author":"L Falchero","year":"2023","unstructured":"Falchero L, Guisier F, Darrason M, Boyer A, Dayen C, Cousin S, et al. Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: results of the IFCT-1905 CLINATEZO real-world study. Lung Cancer. 2023. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107379.","journal-title":"Lung Cancer"},{"key":"3390_CR20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2241","author":"Y Su","year":"2022","unstructured":"Su Y, Luo B, Lu Y, Wang D, Yan J, Zheng J, et al. Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin Cancer Res. 2022. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2241.","journal-title":"Clin Cancer Res"},{"key":"3390_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03858-2","author":"Q Chen","year":"2022","unstructured":"Chen Q, Li Y, Zhang W, Wang C, Yang S, Guo Q. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study. J Cancer Res Clin Oncol. 2022. https:\/\/doi.org\/10.1007\/s00432-021-03858-2.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3390_CR22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1543","author":"OE Rahma","year":"2019","unstructured":"Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res. 2019. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1543.","journal-title":"Clin Cancer Res"},{"key":"3390_CR23","doi-asserted-by":"publisher","unstructured":"Yu L, Xu J, Qiao R, Zhong H, Brueckl WM, Zhong R (2023) Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study. Transl Lung Cancer Res. https:\/\/doi.org\/10.21037\/tlcr-23-260","DOI":"10.21037\/tlcr-23-260"},{"key":"3390_CR24","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S337316","author":"Y-Y Hao","year":"2021","unstructured":"Hao Y-Y, Qiao Y-P, Cheng J-D. Clinical activity and safety of anlotinib combined with PD-1 blockades for patients with previously treated small cell lung cancer. Int J Gen Med. 2021. https:\/\/doi.org\/10.2147\/IJGM.S337316.","journal-title":"Int J Gen Med"},{"key":"3390_CR25","doi-asserted-by":"publisher","unstructured":"Jiang Y, Zhang L, Zhu F, Zhu H, Cao X, Zhang Y (2022) Camrelizumab combined with anlotinib for the treatment of small cell lung cancer: a case report and literature review. Ann Palliat Med. https:\/\/doi.org\/10.21037\/apm-21-3860","DOI":"10.21037\/apm-21-3860"},{"key":"3390_CR26","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0147","author":"G Wu","year":"2022","unstructured":"Wu G, Huang J, Lin L, Yan S, Pan W, Chen Q, et al. Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report. Immunotherapy. 2022. https:\/\/doi.org\/10.2217\/imt-2021-0147.","journal-title":"Immunotherapy"},{"key":"3390_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-04182-6","author":"S Zhou","year":"2022","unstructured":"Zhou S, Ren F, Li C, Jiang L, Meng X, Huang Z. Efficacy and safety of immune checkpoint inhibitors plus anlotinib in small cell lung cancer with brain metastases: a retrospective, multicentre study. J Neurooncol. 2022. https:\/\/doi.org\/10.1007\/s11060-022-04182-6.","journal-title":"J Neurooncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03390-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03390-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03390-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T05:12:12Z","timestamp":1718341932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03390-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["3390"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03390-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval of the study protocol was obtained from Zhejiang Cancer Hospital Institutional Review Board Committee (approval number: IRB-2023-268). Individual consent for this retrospective analysis was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Individual consent for analysis was waived.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publish"}}]}}